5,131 followers
New Research: Tislelizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma in China: a cost-effectiveness analysis: Objective The goal of this study is to compare the cost-effectiveness of… https://t.co/oxOJIJ390f #PublicHea